世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000036459

世界のHERGスクリーニング市場調査レポートー2030年までの予測

Market Research Future

Global HERG Screening Market Research Report - Forecast to 2030

発刊日 2023/10

言語英語

体裁PDF/107ページ

ライセンス/価格107ページ

0000036459

Single
Enterprise

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

市場概要

HERG スクリーニング市場は、予測期間中に 12.50% という大幅な CAGR を記録すると予想されます。想像される治療薬の支持の高まりと冠動脈疾患の増加が、市場の発展に貢献する主要な推進要因です。冠動脈疾患が一般的な疾患になり、心臓病患者の数も増加しているため、市場は今後拡大することが予想されます。研究開発活動の拡大により、市場は発展しています。さらに、創造的な医薬品の承認数の増加が市場の発展を維持すると予想されます。疾患の治療薬の創出と医薬品計画の人気の高まりの直接の結果として市場は発展しています。

レポート詳細

目次

TABLE OF CONTENT

1 EXECUTIVE SUMMARY
1.1 MARKET SYNOPSIS
1.2 MARKET ATTRACTIVENESS ANALYSIS

2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING NOVEL DRUG APPROVALS
4.2.2 INCREASING PREVALENCE OF HEART DISEASES
4.3 RESTRAINT
4.3.1 HIGH COST OF HERG SCREENING PRODUCTS
4.4 OPPORTUNITY
4.4.1 UNTAPPED MARKETS
4.5 IMPACT OF CORONAVIRUS (COVID)-19
4.5.1 OVERVIEW
4.5.2 IMPACT ON PLAYERS
4.5.3 IMPACT ON CLINICAL TRIALS

5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS
5.1.1 R&D AND DESIGNING
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION
5.1.4 MARKETING & SALES
5.1.5 POST-SALES MONITORING
5.2 PORTER’S FIVE FORCES MODEL
5.2.1 BARGAINING POWER OF SUPPLIERS
5.2.2 BARGAINING POWER OF BUYERS
5.2.3 THREAT OF NEW ENTRANTS
5.2.4 THREAT OF SUBSTITUTES
5.2.5 RIVALRY
5.3 TECHNOLOGICAL TRENDS IN GLOBAL HERG SCREENING MARKET
5.3.1 INCREASING TREND OF OUTSOURCING HERG SERVICES
5.3.2 ADVENT OF PATCH CLAMP ASSAY
5.3.3 STRATEGIC INITIATIVES BY PLAYERS IN THE MARKET
5.4 CUSTOMER NEED ANALYSIS
5.4.1 OVERVIEW
5.4.2 CLINICAL TRIAL FOR HERG SCREENING
5.4.3 CAUSE AND EFFECT ANALYSIS

6 GLOBAL HERG SCREENING MARKET, BY TYPE
6.1 OVERVIEW
6.2 GENE KCNH2
6.3 MUTANT KCNH2

7 GLOBAL HERG SCREENING MARKET, BY ION CHANNEL
7.1 OVERVIEW
7.2 VOLTAGE-GATED ION CHANNEL
7.3 LIGAND-GATED ION CHANNEL
7.4 OTHERS

8 GLOBAL HERG SCREENING MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 ANTIARRHYTHMIC
8.3 ANTIPSYCHOTIC
8.4 ANTIBIOTIC
8.5 OTHERS

9 GLOBAL HERG SCREENING MARKET, BY REGION
9.1 OVERVIEW
9.2 AMERICAS
9.2.1 NORTH AMERICA
9.2.1.1 US
9.2.1.2 CANADA
9.2.2 LATIN AMERICA
9.3 EUROPE
9.3.1 WESTERN EUROPE
9.3.1.1 GERMANY
9.3.1.2 FRANCE
9.3.1.3 UK
9.3.1.4 ITALY
9.3.1.5 SPAIN
9.3.1.6 REST OF WESTERN EUROPE
9.3.2 EASTERN EUROPE
9.4 ASIA-PACIFIC
9.4.1 CHINA
9.4.2 JAPAN
9.4.3 INDIA
9.4.4 AUSTRALIA
9.4.5 SOUTH KOREA
9.4.6 REST OF ASIA-PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST
9.5.2 AFRICA

10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 MARKET RANKING ANALYSIS
10.3 COMPETITIVE BENCHMARKING
10.4 KEY DEVELOPMENTS AND GROWTH STRATEGIES
10.4.1 PARTNERSHIP
10.4.2 ACQUISITIONS
10.4.3 COLLABORATION
10.5 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO
10.5.1 SALES & OPERATING PROFIT MARGIN
10.5.2 R&D EXPENDITURE

11 COMPANY PROFILES
11.1 THERMO FISHER SCIENTIFIC INC.
11.1.1 COMPANY OVERVIEW
11.1.2 FINANCIAL OVERVIEW
11.1.3 PRODUCTS/SERVICES OFFERED
11.1.4 KEY DEVELOPMENTS
11.1.5 SWOT ANALYSIS
11.1.6 KEY STRATEGIES
11.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
11.2.1 COMPANY OVERVIEW
11.2.2 FINANCIAL OVERVIEW
11.2.3 PRODUCTS/SERVICES OFFERED
11.2.4 KEY DEVELOPMENTS
11.2.5 SWOT ANALYSIS
11.2.6 KEY STRATEGIES
11.3 MERCK KGAA
11.3.1 COMPANY OVERVIEW
11.3.2 FINANCIAL OVERVIEW
11.3.3 PRODUCTS/SERVICES OFFERED
11.3.4 KEY DEVELOPMENTS
11.3.5 SWOT ANALYSIS
11.3.6 KEY STRATEGIES
11.4 EUROFINS DISCOVERX CORPORATION
11.4.1 COMPANY OVERVIEW
11.4.2 FINANCIAL OVERVIEW
11.4.3 PRODUCTS/SERVICES OFFERED
11.4.4 KEY DEVELOPMENTS
11.4.5 SWOT ANALYSIS
11.4.6 KEY STRATEGIES
11.5 ABCAM PLC.
11.5.1 COMPANY OVERVIEW
11.5.2 FINANCIAL OVERVIEW
11.5.3 PRODUCTS/SERVICES OFFERED
11.5.4 KEY DEVELOPMENTS
11.5.5 SWOT ANALYSIS
11.5.6 KEY STRATEGIES
11.6 CYPROTEX LIMITED
11.6.1 COMPANY OVERVIEW
11.6.2 FINANCIAL OVERVIEW
11.6.3 PRODUCTS/SERVICES OFFERED
11.6.4 KEY DEVELOPMENTS
11.6.5 SWOT ANALYSIS
11.6.6 KEY STRATEGIES
11.7 B‘SYS GMBH
11.7.1 COMPANY OVERVIEW
11.7.2 FINANCIAL OVERVIEW
11.7.3 PRODUCTS/SERVICES OFFERED
11.7.4 KEY DEVELOPMENTS
11.7.5 SWOT ANALYSIS
11.7.6 KEY STRATEGIES
11.8 CREATIVE BIOARRAY
11.8.1 COMPANY OVERVIEW
11.8.2 FINANCIAL OVERVIEW
11.8.3 PRODUCTS/SERVICES OFFERED
11.8.4 KEY DEVELOPMENTS
11.8.5 SWOT ANALYSIS
11.8.6 KEY STRATEGIES
11.9 METRION BIOSCIENCES LTD
11.9.1 COMPANY OVERVIEW
11.9.2 FINANCIAL OVERVIEW
11.9.3 PRODUCTS/SERVICES OFFERED
11.9.4 KEY DEVELOPMENTS
11.9.5 SWOT ANALYSIS
11.9.6 KEY STRATEGIES
11.10 AURORA BIOMED INC.
11.10.1 COMPANY OVERVIEW
11.10.2 FINANCIAL OVERVIEW
11.10.3 PRODUCTS/SERVICES OFFERED
11.10.4 KEY DEVELOPMENTS
11.10.5 SWOT ANALYSIS
11.10.6 KEY STRATEGIES

12 APPENDIX
12.1 REFERENCES
12.2 RELATED REPORTS

この商品のレポートナンバー

0000036459

TOP